Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 8/20 | 0.39 |
| ▸ | CDK2 | P24941 | 8/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27374373 | 1.00 | ADORA2A (0.52) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL27375698 | 0.88 | ADORA2A (0.39) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL27374918 | 0.88 | CDK1 (0.40) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL16769795 | 0.85 | CDK2 (0.54) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL27374408 | 0.85 | HPRT1 (0.40) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL22381492 | 0.84 | CDK1 (0.42) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL14644457 | 0.83 | HPRT1 (0.54) | ADORA2AADORA2BADORA1KMT2AHPRT1 | |
| SCHEMBL18822254 | 0.83 | HPRT1 (0.54) | ADORA2AADORA2BADORA1KMT2AHPRT1 | |
| SCHEMBL27375754 | 0.81 | CDK1 (0.39) | ADORA2AADORA2BADORA1GAACDK1 | |
| SCHEMBL27374409 | 0.78 | GAA (0.38) | GAACDK1CDK2CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | ADORA2A 14/4885ADORA2B 23/4885ADORA1 6/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | ADORA2A 14/4885ADORA2B 23/4885ADORA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.